Haobo Pharmaceuticals announces completion of 50 million US dollars in Series B+ financing.

Innovative drug R&D company Haobo Medicine announced the completion of a $50 million Series B+ round of financing. This round of financing was led by globally renowned industrial investment institutions, with additional investments from Qiming Venture Partners, DHVC, Yuansheng Capital, Yuansheng Ventures, Han Kang Capital, Charba Investment, and other investment institutions.